Details of the Drug

General Information of Drug (ID: DMMF5IE)

Drug Name
GS-9883
Synonyms
Bictegravir; Bictegravir (USAN/INN); Bictegravir [INN]; Bictegravir [USAN:INN]; SB18851; SOLUWJRYJLAZCX-LYOVBCGYSA-N; (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide; 1611493-60-7; 8GB79LOJ07; BCP25703; BDBM330048; CHEMBL3989866; DB11799; GS 9883; GS-9883; GS-9883-01; SCHEMBL15914278; UNII-8GB79LOJ07
Affected Organisms
Human Immunodeficiency Virus
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 449.4
Logarithm of the Partition Coefficient (xlogp) 2.7
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
Absorption
The drug is rapidly absorbed []
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2-4 h []
Elimination
About 1% of the bictegravir dose is excreted from the urine in unchanged form [1]
Half-life
The concentration or amount of drug in body reduced by one-half in 17.3 hours []
Metabolism
The drug is metabolized via the liver []
Vd
The volume of distribution (Vd) of drug is 0.2 L/kg [1]
Chemical Identifiers
Formula
C21H18F3N3O5
IUPAC Name
(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
Canonical SMILES
C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
InChI
SOLUWJRYJLAZCX-LYOVBCGYSA-N
InChIKey
1S/C21H18F3N3O5/c22-9-3-14(23)12(15(24)4-9)6-25-20(30)13-7-26-8-16-27(10-1-2-11(5-10)32-16)21(31)17(26)19(29)18(13)28/h3-4,7,10-11,16,29H,1-2,5-6,8H2,(H,25,30)/t10-,11+,16+/m0/s1
Cross-matching ID
PubChem CID
90311989
CAS Number
1611493-60-7
UNII
8GB79LOJ07
DrugBank ID
DB11799
INTEDE ID
DR0212

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [2]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1CInfected Adults
2 Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682.